Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Dixon

Urology Ashland, KY Medical Doctor

NPI 1225026438 CMS profile 191642

336 29Th St, Ashland, KY 41101

Open in the dashboard

General payments

$2,839

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Dixon of Ashland, KY is reported in the CMS Open Payments database as having received $2,839 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2024 General $21 1
2023 General $335 18
2022 General $854 57
2021 General $665 45
2020 General $405 29
2019 General $536 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Dixon
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Timothy Dixon were reported at $24. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Timothy Dixon Urology median Middle half National median
2019 $536 $480 $147–$1,201 $163
2020 $405 $246 $87–$645 $114
2021 $665 $358 $111–$1,000 $132
2022 $854 $476 $143–$1,263 $149
2023 $335 $560 $168–$1,461 $160
2024 $21 $563 $170–$1,464 $164
2025 $24 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $777 63 payments
  2. AbbVie, Inc. $304 21 payments
  3. Antares Pharma, Inc. $242 13 payments
  4. Pfizer Inc. $224 15 payments
  5. Janssen Biotech, Inc. $217 12 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $195 15 payments
  7. Endo Pharmaceuticals Inc. $166 12 payments
  8. Myriad Genetic Laboratories, Inc. $92 6 payments
  9. Medtronic USA, Inc. $90 3 payments
  10. Axonics Modulation Technologies, Inc. $88 6 payments
  11. Other $445 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,735 184 payments
  2. Education $81 3 payments
  3. Debt forgiveness $23 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $864 67 payments
  2. MYRBETRIQ $308 32 payments
  3. LUPRON DEPOT $231 16 payments
  4. Nubeqa $195 15 payments
  5. ORGOVYX $184 12 payments
  6. XIAFLEX $166 12 payments
  7. ERLEADA $165 10 payments
  8. NOCDURNA $140 6 payments
  9. XYOSTED $140 6 payments
  10. TLANDO $119 5 payments
  11. Other $1,044 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

137

Median for Urology: 1,053

Drug cost

$20,113

Median for Urology: $101,464

Branded share of claims

37.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 30 $18,731
Tamsulosin Hcl Generic 53 $647
Finasteride Generic 33 $418
Oxybutynin Chloride Er Oxybutynin Chloride Brand 21 $317

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • PFIZER INC. $10
$10 — —
ORGOVYX
  • PFIZER INC. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record